- Home
- AGEN vs IKNA Comparison
AGEN vs IKNA Comparison
Compare AGEN & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- IKNA
- Stock Information
- Founded
- AGEN 1994
- IKNA 2016
- Country
- AGEN United States
- IKNA United States
- Employees
- AGEN N/A
- IKNA N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- AGEN Health Care
- IKNA Health Care
- Exchange
- AGEN Nasdaq
- IKNA Nasdaq
- Market Cap
- AGEN 96.2M
- IKNA 81.6M
- IPO Year
- AGEN 2000
- IKNA 2021
- Fundamental
- Price
- AGEN $3.32
- IKNA $1.39
- Analyst Decision
- AGEN Buy
- IKNA Buy
- Analyst Count
- AGEN 3
- IKNA 2
- Target Price
- AGEN $10.50
- IKNA $3.00
- AVG Volume (30 Days)
- AGEN 357.6K
- IKNA 164.1K
- Earning Date
- AGEN 03-13-2025
- IKNA 03-11-2025
- Dividend Yield
- AGEN N/A
- IKNA N/A
- EPS Growth
- AGEN N/A
- IKNA N/A
- EPS
- AGEN N/A
- IKNA N/A
- Revenue
- AGEN $160,427,000.00
- IKNA $659,000.00
- Revenue This Year
- AGEN N/A
- IKNA N/A
- Revenue Next Year
- AGEN $26.02
- IKNA N/A
- P/E Ratio
- AGEN N/A
- IKNA N/A
- Revenue Growth
- AGEN 59.00
- IKNA N/A
- 52 Week Low
- AGEN $2.50
- IKNA $1.22
- 52 Week High
- AGEN $19.69
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- AGEN 45.96
- IKNA 43.10
- Support Level
- AGEN $3.09
- IKNA $1.40
- Resistance Level
- AGEN $3.68
- IKNA $1.53
- Average True Range (ATR)
- AGEN 0.25
- IKNA 0.06
- MACD
- AGEN -0.03
- IKNA 0.00
- Stochastic Oscillator
- AGEN 23.00
- IKNA 28.57
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.